A survey found that 68% of 156 executives who direct or influence marketing at U.S. and European drugmakers think the business model is broken. Seventy-six percent said budget pressure and health-system pricing will be the industry's biggest challenge for the next two years. Others expect issues to include having to prove cost-effectiveness and dealing with market-access restriction.
Execs: Pharma business model is broken
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||